A multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric cancer
Date
2013
Authors
Karabulut, Bülent
Özdemir, Feyyaz
Tunalı, Didem
Journal Title
Journal ISSN
Volume Title
Publisher
Imprimatur Publications
Abstract
Purpose: Albeit the majority of gastric cancers occur at advanced age, little is known regarding the optimal systemic treatment of elderly patients with advanced gastric cancer (AGC).
Methods: Patients with AGC who were >= 65 years old and were treated with carboplatin (area under the curve/AUG 5, on day 1, every 3 weeks) plus docetaxel (75 mg/m(2), on day 1, every 3 weeks) at 3 institutions were included in this retrospective analysis. The efficacy and the safety data of the regimen were analyzed.
Results: A total of 30 patients were enrolled. They received 128 cycles of chemotherapy, with a median of 4 cycles (range 2-8). Complete response (CR) and partial response (PR) were observed in 2 (6.7%) and 10 patients (33.3%), respectively, amounting to an overall objective response rate (ORR) of 40%. Seven patients (23.3%) had disease stabilization (SD), and 11(36.7%) showed disease progression (PD). The most common grade 3-4 toxicity was neutropenia occurring in 19 patients (63.3%). The mean progression-free survival (PFS) was 6.0 +/- 0.5 months (95% CI: 5.0-7.4), and the mean overall survival (OS) 12.0 +/- 1.0 months (95% CI: 9.2-12.1).
Conclusion: Carboplatin plus docetaxel seems to be an active and well-tolerated regimen, representing a valuable alternative to cisplatin- and/or fluoropyrimidine-containing regimens for the treatment of elderly patients with AGC.
Description
Keywords
Oncology, Carboplatin, Docetaxel, Elderly, Gastric cancer, Phase-II trial, 1st-line chemotherapy, Systemic treatment, RAndomized-trial, Cisplatin, Oxaliplatin, Fluorouracil, Adenocarcinoma, Paclitaxel, Older
Citation
Kurt, E. vd. (2013). “A multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric cancer”. Journal of BUON, 18(1), 147-153.